Uncategorized
Sermorelin vs CJC-1295: GHRH Research Comparison Guide
May
- Sermorelin is the unmodified 29-residue GHRH 1-29 analogue (MW 3357.9 Da) — short half-life, useful for pulsatile receptor activation research.
- CJC-1295 (MOD-GRF 1-29, MW 3367.9 Da) is the same 29-residue backbone with DAC modification enabling albumin binding and extended half-life.
- The pair enables research-tool comparison of short vs sustained GHRH receptor occupancy at matched receptor binding magnitudes.
Two GHRH Analogues, Same Backbone, Different Pharmacokinetics
Sermorelin and CJC-1295 (the GHRH component of the CJC-1295 + Ipamorelin Blend) share the same 29-residue GHRH-receptor-binding backbone but differ in pharmacokinetic profile. Sermorelin is the unmodified GHRH 1-29 sequence; CJC-1295 adds the DAC (drug-affinity complex) modification enabling non-covalent albumin binding and substantially extended preclinical half-life. The pair enables research-tool comparison of short vs sustained GHRH-receptor occupancy. Both are available at Advanced Peptide Science within the Growth Hormone & Performance category.
Research Background
Sermorelin was the first synthetic GHRH analogue developed for research, representing the minimal biologically active fragment of the native human 44-residue GHRH protein. The 29-residue N-terminal fragment retains full GHRH-receptor agonism while simplifying synthesis and characterisation. CJC-1295 (also called MOD-GRF 1-29) emerged from research optimising the Sermorelin backbone for extended pharmacokinetics — the DAC modification was selected to enable non-covalent albumin binding without disrupting receptor binding. The third member of the GHRH-analogue research class is Tesamorelin, which retains the full 44-residue GHRH backbone with N-terminal trans-3-hexenoic acid modification — distinct from both the truncated Sermorelin/CJC sequence and from the DAC modification strategy.
Mechanism Comparison
Both Sermorelin and CJC-1295 act through GHRH receptor (GHRHR) — a class B G-protein-coupled receptor on pituitary somatotrophs coupled to Gs/cAMP signalling. Downstream pathways are identical: cAMP/PKA activation drives GH gene transcription and baseline GH secretion. The research-relevant difference lies in receptor occupancy duration. Sermorelin has a short preclinical half-life (minutes), enabling pulsatile receptor activation patterns. CJC-1295 has a substantially extended preclinical half-life via albumin binding, enabling sustained receptor activation patterns.
Key Research Findings: Short vs Sustained Activation
Pulsatile vs Sustained Receptor Occupancy
The GH axis is naturally pulsatile — native GHRH is released in discrete bursts driving corresponding GH secretion pulses. Sermorelin enables research mimicking this pulsatile pattern. CJC-1295’s sustained receptor occupancy enables research investigating what happens when the natural pulsatility is replaced by continuous receptor activation — a research-tool framework for dissecting pulsatile vs sustained GH-axis signalling effects.
Receptor Desensitisation Research
Sustained receptor activation can induce receptor desensitisation through GPCR downregulation and internalisation mechanisms. Comparative research using Sermorelin (pulsatile) vs CJC-1295 (sustained) enables investigation of GHRH receptor desensitisation kinetics — relevant to long-term GH-axis pharmacology research.
GHRP Co-Administration Studies
Both compounds can be co-administered with GHRPs (GHRP-6, GHRP-2, Hexarelin, or Ipamorelin) for combined GHRH + GHS-R1a research. The CJC-1295 + Ipamorelin pairing is the standard reference combination, but comparable Sermorelin + GHRP combinations enable research using short-acting GHRH alongside GHRP co-activation.
Research Applications
Sermorelin is preferred for research designs requiring short receptor occupancy or pulsatile receptor activation. CJC-1295 (within the CJC-1295 + Ipamorelin Blend) is preferred for research designs requiring sustained receptor occupancy. The combined comparison enables fundamental research into pulsatile vs continuous GHRH receptor signalling pharmacology.
Side-by-Side Research Specifications
| Parameter | Sermorelin | CJC-1295 (in blend) |
|---|---|---|
| Molecular Weight | 3357.9 Da | 3367.9 Da |
| Sequence Length | 29 amino acids | 29 amino acids |
| Modification | None (native GHRH 1-29) | DAC modification (albumin binding) |
| Preclinical Half-Life | Short (minutes) | Substantially extended |
| Receptor Pattern | Pulsatile activation | Sustained activation |
| Receptor Target | GHRH receptor (GHRHR) | GHRH receptor (GHRHR) |
Frequently Asked Questions
What is the key difference between Sermorelin and CJC-1295?
Both share the same 29-residue GHRH-receptor-binding sequence. The difference is the DAC modification on CJC-1295 enabling non-covalent albumin binding and substantially extended preclinical half-life. Sermorelin is short-acting; CJC-1295 is sustained-acting.
When is short-acting GHRH preferred?
For research designs investigating pulsatile receptor activation patterns mimicking native GHRH release. Sermorelin’s short half-life enables clean pulsatile receptor occupancy that CJC-1295’s sustained binding cannot achieve.
How does Tesamorelin fit in?
Tesamorelin is the full-length (44-residue) GHRH analogue with trans-3-hexenoic acid N-terminal modification — a different sequence and modification strategy from both Sermorelin (truncated, unmodified) and CJC-1295 (truncated, DAC-modified).
Are both compounds approved for human use?
Advanced Peptide Science supplies Sermorelin and CJC-1295 exclusively for in vitro and in vivo scientific research. Not for human consumption. Research use only.
For Research Use Only. Not for human consumption. Not intended to diagnose, treat, cure, or prevent any disease.
